Natera, Inc. is a diagnostics company that develops and commercializes cell-free DNA (cfDNA) tests for oncology, women’s health, and organ health. In oncology, the company offers Signatera, a personalized circulating tumor DNA test for molecular residual disease assessment and recurrence monitoring in solid tumors, and acquired Foresight Diagnostics in December 2025 to expand into lymphoma and early cancer detection. In women’s health, it provides Panorama, a non-invasive prenatal test for fetal aneuploidies and genetic conditions. In organ health, it offers tests to assess transplant rejection in kidney, heart, and lung recipients using donor-derived cfDNA. Natera utilizes proprietary massively multiplexed polymerase chain reaction and bioinformatics algorithms to detect genetic variations from small blood samples. The company sells directly in the United States and through a global network of laboratory and distribution partners, utilizing its Constellation cloud platform for algorithm access. Founded in 2004, Natera operates CLIA-certified laboratories and maintains a portfolio of issued and pending patents.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage natera.com
Sector Healthcare IR page investor.natera.com/overview/default.aspx
Tags
cell-free dna, oncology, women's health, organ health, molecular residual disease, non-invasive prenatal testing, transplant rejection, bioinformatics, liquid biopsy, genetic testing, Signatera, Panorama, Prospera, Constellation, Foresight Diagnostics
Press page natera.com/company/news

Metrics

Valuation  
Market cap $ 46.112B
Market cap (USD) $ 46.112B
P/E -282.71
PEG —
P/BV 24.66
P/S 15.85
P/OCF 216.71
P/FCF 878.88
Dividend yield —
Turnover / mcap —
Returns  
ROE -14.3%
ROI -11.6%
ROIC -13.0%
Profit margin -9.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 127
Quality score -44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 2.306B 1.697B 1.083B 820.222M 625.486M 391.005M 302.328M 257.654M 210.939M 217.074M 190.355M 159.289M
Net profit -208.16M -190.426M -434.801M -547.799M -471.716M -229.7M -124.827M -128.154M -136.314M -95.765M -70.275M -5.152M
Free cash flow 109.113M 69.241M -286.154M -479.198M -376.266M -202.116M -68.412M -74.461M -106.659M -97.038M -45.684M 533K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 229.09 158.3 62.64 40.17 93.39 99.52 33.69 13.96 8.99 11.71 10.8 —
Price performance 12m 0.45 1.53 0.56 -0.57 -0.06 1.95 1.41 0.55 -0.23 0.08 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 13.4M 8.25M 62.2M 53.4M 78.6M 122M 244M 278M 314M 297M
↳ YoY growth +128.5% -38.4% +654.0% -14.3% +47.3% +55.4% +100.2% +13.9% +12.9% -5.6%
↳ 5y CAGR +55.1% +68.0% +55.6% +96.9% +34.9% +42.6% +30.4%
Borrowings, current (USD) 49.6M 50.1M 50.2M 50.1M 50.1M 50.1M 80.4M 80.4M 80.4M 80.3M
Lease liabilities (USD) — — — 32M 28.5M 66.8M 84.2M 78.6M 107M 134M
Cash and deposits (USD) 15.3M 12.6M 46.4M 61.9M 48.7M 84.4M 466M 642M 946M 1.08B
Intangible assets (USD) — — — — — — — — 10.9M 374M
Right-of-use assets (USD) — — — 23.7M 21.4M 59M 71.9M 56.5M 86.1M 109M
Net debt (borrowings + leases - cash) (USD) 34.4M 37.5M 3.75M 20.2M 29.9M 32.5M -301M -483M -758M -862M
Cash flow detail
Operating cash flow (USD) -73.9M -96.8M -70.6M -63.4M -183M -335M -432M -247M 136M 215M
Purchases of property, plant and equipment (USD) -23.1M -9.87M -3.88M -4.97M -19.6M -41M -47.7M -39.2M -66.4M -106M
Purchases of intangible assets (USD) — — — — — — — — -10.5M -33M
Change in receivables (cash effect) (USD) -8.52M 5M -18.1M 2.42M -25.8M -43.4M -124M -33.9M -35.9M 20.8M
Change in inventories (cash effect) (USD) -431,000 -3.09M -4.9M 917,000 -7.47M -7.51M -8.26M -5.35M -3.99M -20.9M
Change in payables (cash effect) (USD) 1.26M 217,000 3.78M -6.26M -118,000 19.2M 5.46M -15.5M 13.2M 753,000
Interest paid (cash effect) (USD) — -3.57M -7.91M -12.5M -3.3M -7.08M -8.06M -11.3M -7.9M -4.07M
Income taxes paid (cash effect) (USD) — -177,000 -332,000 -2.15M -67,000 -283,000 -549,000 -295,000 -1.31M -499,000
Share-based compensation (USD) 10.6M 11.4M 14.2M 28.6M 50.2M 115M 152M 192M 274M 354M
Operating cash flow before change in receivables (USD) -65.4M -102M -52.5M -65.9M -157M -292M -307M -213M 172M 195M
Free cash flow (OCF - PPE - intangibles) (USD) -97M -107M -74.5M -68.4M -202M -376M -479M -286M 69.2M 76.1M
Income detail
Research and development expense (USD) 41.9M 50.1M 51.4M 51.4M 100M 264M 316M 321M 404M 624M
↳ 5y CAGR +34.8% +24.3% +29.3% +44.6% +44.6% +44.2% +51.1% +44.2%
Total comprehensive income (USD) -95.1M -136M -128M -123M -226M -478M -562M -422M -188M -208M
Comprehensive income to owners (USD) -95.1M -136M -128M -123M -226M -478M -562M -422M -188M -208M
Provision for credit losses (USD) 984,000 143,000 -41,000 1.14M 1.35M -156,000 1.77M 2.65M 1.28M 1.61M
Credit cost ratio (credit losses / average receivables) (%) 10.2% 1.3% 0.1% 2.0% 2.1% 0.2% 1.0% 1.0% 0.4% 0.5%
Reported Mar 16, 2017 Mar 15, 2018 Mar 15, 2019 Mar 2, 2020 Feb 26, 2021 Feb 25, 2022 Mar 1, 2023 Feb 29, 2024 Feb 27, 2026 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

11/05/2026

Download(opens in new window)PDF 118 KB

New data at SITC includes real-world analysis highlighting that Signatera can inform immunotherapy duration and optimize treatment

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present important new Signatera data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 4–8 in Phoenix, Arizona.

Immune checkpoint inhibitors (ICIs) have transformed treatment for many metastatic cancers, and some patients achieve durable disease control.1 However, it remains challenging for clinicians to determine how long to continue therapy, since imaging alone is prone to error and cannot show whether disease has cleared at the molecular level.2,3 As a result, treatment duration remains an open question, particularly for patients who achieve a durable clinical response.

A real-world analysis at SITC studied outcomes of 424 patients treated with first-line immunotherapy across stage IV melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). The Signatera test was used to identify complete molecular responders (CMRs), defined as patients with two consecutive negative results. Findings showed:

  • Improved survival in Signatera MRD-negative patients: CMRs had a 36-month overall survival (OS) of 93.2% vs. 77.9% in all other patients (HR 0.24; P=0.0003).
  • Favorable survival across tumor types: At 36 months, OS in CMRs ranged from 83.1% (NSCLC) to 100% (MSI-H CRC).
  • No significant survival difference with early ICI discontinuation: OS for CMRs who remained on IO was 93.5% vs. those who stopped (89.4%) (P=0.42).

“For patients with metastatic cancer who achieve a durable response, deciding how long to continue immunotherapy is one of the most difficult clinical decisions,” said Meghan J. Mooradian, MD, Cutaneous Medical Oncology, Mass General Brigham Cancer Institute, and lead author of the study. “Because imaging alone may not fully capture whether disease has been completely cleared, our findings support further investigation of molecular response as a biomarker to help personalize treatment duration and identify patients who may discontinue therapy early.”

“Melanoma, kidney, lung, and colorectal cancers differ biologically, yet sustained Signatera negativity was associated with favorable survival in each,” said Alexey Aleshin, MD, Corporate Chief Medical Officer and General Manager, Oncology, Natera. “These data support the role of Signatera in identifying exceptional ICI responders who may be able to de-escalate treatment.”

References

  1. Wolchok JD, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 2025;392:11-22.
  2. Steimle AK, et al. Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma. Cancers 2026;18(18):3032.
  3. Anagnostou V, et al. Immuno-oncology trial endpoints: Capturing clinically meaningful activity. Clin Cancer Res 2017;23(17):4959-69.

About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder, Colorado. For more information, visit www.natera.com .

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov .

Investor Relations: Mike Brophy, CFO, Natera, Inc., [email protected]

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]

Source: Natera, Inc.

View all news

Natera Reports Third Quarter 2026 Financial Results Bull 6 Bear 0 Results

11/05/2026

Download(opens in new window)PDF 182 KB

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026.

Recent Financial Highlights

  • Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.
  • Generated a gross margin 1 of 64.7% in the third quarter of 2026, compared to a gross margin 1 of 64.9% in the third quarter of 2025. Excluding revenue true-ups, third quarter non-GAAP gross margin 2 increased by 137 basis points over the second quarter of 2026.
  • Processed approximately 1,093,100 tests in the third quarter of 2026, compared to approximately 893,600 tests in the third quarter of 2025, an increase of 22.3%.
  • Processed approximately 339,500 oncology tests in the third quarter of 2026, compared to approximately 211,000 in the third quarter of 2025, an increase of 60.9%. Clinical molecular residual disease (MRD) oncology units grew 32,700 units over the second quarter of 2026.
  • Increased cash by approximately $5.7 million 3 as of September 30, 2026 compared to June 30, 2026.
  • Raised 2026 annual revenue guidance by $140 million at the midpoint, from $2.850 billion - $2.910 billion to $3.005 billion - $3.035 billion.

Third Quarter Ended September 30, 2026 Financial Results

Total revenues were $794.0 million in the third quarter of 2026 compared to $592.2 million in the third quarter of 2025, an increase of 34.1%. The increase in revenues was driven by an increase in volume and average selling price improvements.

Natera processed approximately 1,093,100 tests in the third quarter of 2026, including approximately 1,080,300 tests accessioned in its laboratory, compared to approximately 893,600 tests processed, including approximately 879,700 tests accessioned in its laboratory, in the third quarter of 2025.

In the third quarter of 2026, Natera recognized revenue on approximately 1,024,800 tests for which results were reported to customers in the period (tests reported), including approximately 1,012,100 tests reported from its laboratory, compared to approximately 832,900 tests reported, including approximately 819,900 tests reported from its laboratory, in the third quarter of 2025, an increase of 23.0% from the prior period.

Gross profit1 for the three months ended September 30, 2026 and 2025 was $513.5 million and $384.4 million, respectively, representing a gross margin1 of 64.7% and 64.9%, respectively. This was primarily as a result of higher revenues and continued progress in reducing cost of revenues, offset by a smaller benefit from changes in estimates. Changes in estimates for the three months ended September 30, 2026 and 2025 increased revenue and, as a result, increased gross margin1 by 1.5% and 3.6%, respectively, and increased gross profit1 by $32.3 million and $55.1 million, respectively. The decrease in the change in estimate reflects the continued accumulation of historical collection experience, which has resulted in our estimates of variable consideration at the time of revenue recognition more closely approximating subsequent cash collections.

Gross margin1 for the three months ended June 30, 2026 was 64.5%. Excluding the change in estimates in revenue accruals of approximately $32.3 million and $52.3 million during the three months ended September 30, 2026 and June 30, 2026, respectively, Natera's non-GAAP gross margin2 increased by approximately 1.4% sequentially.

Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the third quarter of 2026 was $576.1 million, compared to $482.0 million in the same period of the prior year, an increase of 19.5%. The increase was primarily driven by headcount growth to support new product offerings as well as increases in clinical trial expenses. Amortization of acquired intangible assets for the third quarter of 2026 was $5.7 million. No such amortization occurred in the third quarter of 2025.

Loss from operations for the third quarter of 2026 was $68.3 million compared to $97.6 million for the same period of the prior year.

Natera’s net loss for the third quarter of 2026 was $59.9 million, or ($0.42) per diluted share, compared to a net loss of $87.5 million, or ($0.64) per diluted share, in the third quarter of 2025. Weighted average shares outstanding were 144.1 million in the third quarter of 2026 compared to 137.2 million for the same period in the prior year.

At September 30, 2026, Natera held approximately $1,097.2 million in cash, cash equivalents, and restricted cash, compared to $1,076.1 million as of December 31, 2025. As of September 30, 2026, Natera had a total outstanding debt balance of $80.3 million, including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.

Financial Outlook

Natera anticipates 2026 total revenue of $3.005 billion to $3.035 billion; gross margin1 to be approximately 64% to 66%; selling, general and administrative costs to be approximately $1.225 billion to $1.300 billion; research and development costs to be $825 million to $925 million; and cash flow to be positive.

Test Volume Summary

Unit QTD 2026 QTD 2025 Definition
Tests processed 1,093,100 893,600 Tests accessioned in our laboratory plus units processed outside of our laboratory
Tests accessioned 1,080,300 879,700 Tests accessioned in our laboratory
Tests reported 1,024,800 832,900 Total tests reported
Tests reported in our laboratory 1,012,100 819,900 Total tests reported in our laboratory less units reported outside of our laboratory

About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder, Colorado. For more information, visit www.natera.com .

Conference Call Information

Event: Natera’s Third Quarter Financial Results Conference Call
Date: Thursday, November 5, 2026
Time: 1:30 p.m. PT (4:30 p.m. ET)
Live Dial-In: 1-833-461-5787 (Domestic)1-585-542-9983 (International)
Conference ID: 221 556 643
Webcast Link: https://events.q4inc.com/attendee/221556643

Forward-Looking Statements

This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our market opportunity, anticipated products and launch schedules, reimbursement coverage, product costs, and gross margins, commercial and strategic partnerships and acquisitions, user experience, clinical trials and studies, and our strategies, goals and general business and market conditions, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through our laboratory partners; we have incurred net losses since our inception and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period to period; unless otherwise indicated, all financial data for the current and prior quarters are unaudited and subject to adjustment in connection with the completion of our quarterly and annual financial reporting processes; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; our products may not perform as expected; the results of our clinical studies may not support the use and reimbursement of our tests, particularly for microdeletions screening, and may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratories becomes inoperable, we will be unable to perform our tests and our business may be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for our tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors; we could incur substantial costs and delays complying with governmental regulations; litigation and other regulatory or governmental proceedings related to our intellectual property or the commercialization of our tests, are costly, time-consuming, could result in our obligation to pay material judgments or incur material settlement costs, and could limit our ability to commercialize our tests; and any inability to effectively protect our proprietary technology could harm our competitive position or our brand.

We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic reports on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC’s website at www.sec.gov .

We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, you should not place undue reliance on our forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

References:

  1. Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues.
  2. Excluding the change in estimates in revenue accruals of approximately $32.3 million and $52.3 million during the three months ended September 30, 2026 and June 30, 2026, respectively, Natera’s non-GAAP gross margin increased by approximately 1.4% sequentially.
  3. Includes GAAP cash, cash equivalents and restricted cash.
Natera, Inc.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except shares)
September 30, 2026 December 31, 2025
(1)
Assets
Current assets:
Cash, cash equivalents and restricted cash $ 1,097,195 $ 1,076,140
Accounts receivable, net of allowance of $6,231 in 2026 and $8,018 in 2025 471,354 296,528
Inventory 91,704 68,443
Prepaid expenses and other current assets 62,359 55,828
Total current assets 1,722,612 1,496,939
Property and equipment, net 353,954 241,184
Operating lease right-of-use assets 129,445 108,541
Goodwill 141,100 141,070
Intangible assets 353,044 373,713
Other assets 48,260 36,897
Total assets $ 2,748,415 $ 2,398,344
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable $ 120,176 $ 33,156
Accrued compensation 112,541 92,603
Contingent consideration payable, current portion 45,873 21,580
Deferred revenue, current portion 36,596 24,907
Short-term debt financing 80,295 80,323
Other accrued liabilities 217,416 188,659
Total current liabilities 612,897 441,228
Contingent consideration payable, long-term portion 83,187 96,780
Deferred tax liability, long-term portion 701 701
Operating lease liabilities, long-term portion 142,617 118,473
Deferred revenue, long-term portion 15,781 17,062
Other liabilities 23,674 11,687
Total liabilities 878,857 685,931
Commitments and contingencies
Stockholders’ equity:
Common stock (2) 14 14
Additional paid in capital 4,857,666 4,488,679
Accumulated deficit (2,987,994 ) (2,776,022 )
Accumulated other comprehensive loss (128 ) (258 )
Total stockholders’ equity 1,869,558 1,712,413
Total liabilities and stockholders’ equity $ 2,748,415 $ 2,398,344
(1) The consolidated balance sheet at December 31, 2025 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
(2) As of September 30, 2026 and December 31, 2025, there were approximately 144,345,000 and 139,693,000 shares of common stock, respectively, issued and outstanding.
Natera, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except per share data)
Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
Revenues
Product revenues $ 789,981 $ 590,197 $ 2,231,778 $ 1,634,660
Licensing and other revenues 4,000 1,986 11,599 5,955
Total revenues 793,981 592,183 2,243,377 1,640,615
Cost and expenses
Cost of product revenues 279,636 207,253 791,435 591,397
Cost of licensing and other revenues 871 548 2,443 1,465
Research and development 242,433 173,412 681,206 448,917
Selling, general and administrative 333,656 308,546 988,798 885,962
Amortization of acquired intangible assets 5,707 — 17,123 —
Total cost and expenses 862,303 689,759 2,481,005 1,927,741
Loss from operations (68,322 ) (97,576 ) (237,628 ) (287,126 )
Interest expense (903 ) (1,045 ) (2,685 ) (3,078 )
Interest and other income, net 9,612 11,284 28,665 35,441
Loss before income taxes (59,613 ) (87,337 ) (211,648 ) (254,763 )
Income tax benefit (expense) (299 ) (207 ) (324 ) (655 )
Net loss $ (59,912 ) $ (87,544 ) $ (211,972 ) $ (255,418 )
Unrealized gain (loss) on available-for-sale securities and foreign currency translation adjustment (20 ) 100 130 157
Comprehensive loss $ (59,932 ) $ (87,444 ) $ (211,842 ) $ (255,261 )
Net loss per share:
Basic and diluted $ (0.42 ) $ (0.64 ) $ (1.48 ) $ (1.88 )
Weighted-average number of shares used in computing basic and diluted net loss per share:
Basic and diluted 144,067 137,187 142,959 136,181

Investor Relations
Mike Brophy, CFO, Natera, Inc., [email protected]

Media
Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]

Source: Natera, Inc.

View all news

Natera Announces Leadership Transition Bull 2 Bear 0 Management

11/05/2026

Download(opens in new window)PDF 111 KB

Solomon Moshkevich appointed Chief Executive Officer to lead the company's next phase of expansion

Company separately reports third quarter 2026 financial results

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Solomon Moshkevich has been appointed Chief Executive Officer and a member of the Board of Directors, effective immediately.

Steve Chapman will step down from the CEO role and remain a consultant to the company for an extended period of time. Chapman will also remain an advisor to the Board of Directors.

Moshkevich joined Natera in 2011. In his 15 years with the company, he has built and led multiple teams, including global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, international sales and business development, regulatory and quality affairs, and portfolio strategy. He has played a leading role in the development, clinical validation, and commercial success of all of Natera’s cell-free DNA products including Panorama™, Prospera™, and Signatera™. Most recently, Moshkevich served as the company’s President, Clinical Diagnostics, and he has played an integral role in the company’s expansion into oncology, overseeing a period of tremendous growth as the company’s first General Manager of Oncology.

“It is my pleasure to introduce Solomon as the next CEO of Natera,” said Steve Chapman. “I hired Solomon in 2011, and he’s been an integral part of our success ever since. Solomon has been deeply involved with every major decision the company has made, and has my full support. I’m extremely proud of what we’ve accomplished together. During my tenure as CEO, we have made an extraordinary impact for millions of patients, while growing our revenue roughly tenfold and creating significant value for shareholders. We achieved this by building an exceptional team that is positioned to build on our momentum and deliver on the strategy ahead. This was the right time for a transition, and I look forward to supporting the company going forward.”

“On behalf of the Board, I want to thank Steve for his excellent leadership and dedication to Natera,” said Matthew Rabinowitz, PhD, Executive Chairman and Co-Founder of Natera. “Steve led Natera’s growth in women’s health and our expansion into oncology and organ health. He has had an indelible impact on our company and on the patients who rely on our tests every day. During his tenure, Natera launched many products that have dramatically impacted patient care, including Panorama and Signatera, which have been transformative in women’s health and cancer care. It also gives me great pride that, for the second time, we are promoting to the role of CEO a member of the Natera team who has been deeply connected to this business. Solomon has spent 15 years building Natera, initially as a leader in reproductive health, and most recently as an instrumental leader in our expansion into organ health and oncology.”

“I am honored to lead this extraordinary team into our next chapter of innovation and expansion as Natera’s CEO,” said Moshkevich. “I’m deeply grateful to Steve for his leadership, his mentorship, and his lasting impact on Natera’s growth and on the patients we serve. At Natera, we are building an enduring healthcare company that is transforming the practice of medicine by enabling earlier, more targeted interventions for those who need them and sparing unnecessary treatment for those who don’t. In the years ahead, we intend to generate more diagnostic insights from every clinical sample, bring novel technologies to new patient populations, integrate more seamlessly at the point of care, and help shape the next frontier of precision medicine.”

Third quarter 2026 results

Natera separately reported its third quarter 2026 financial results today. The earnings release is available on the investor relations section of Natera’s website at investor.natera.com . Management will host a conference call at 4:30 p.m. ET.

About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder, Colorado. For more information, visit www.natera.com .

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov .

Investor Relations: Mike Brophy, CFO, Natera, Inc., [email protected]

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]

Source: Natera, Inc.

View all news

Prompts

Natera, Inc. (ticker NTRA), listed in United States.

ETFs Holding Natera, Inc.

ETF Weight in ETF Shares Market value As of
DRKY 22.84% 13,849 $ 3.995M Nov 17, 2026
HELX 7.46% 7,679 $ 2.084M Jun 30, 2026
LRNZ 5.46% 8,428 $ 2.288M Jun 30, 2026
ARKG 4.48% 283,446 $ 81.482M Nov 18, 2026
XOVR 3.70% 297,907 $ 80.867M Jun 30, 2026
FMED 3.30% 5,280 $ 1.7M Aug 31, 2026
FCUS 2.63% 6,801 $ 1.962M Nov 17, 2026
SAMM 2.49% 2,785 $ 755.988K Jun 30, 2026
WUGI 2.42% 3,222 $ 874.612K Jun 30, 2026
FFOX 2.03% 17,937 $ 4.869M Jun 30, 2026
SSMG 2.01% 240 $ 64.262K Jul 31, 2026
FEMG 1.77% 435 $ 118.081K Jun 30, 2026
ATFV 1.76% 12,848 $ 3.488M Jun 30, 2026
BCSM 1.75% 2,138 $ 580.36K Jun 30, 2026
MEDI 1.70% 2,321 $ 749.544K Nov 12, 2026
HFGO 1.62% 8,849 $ 0.00 Nov 18, 2026
GDOC 1.57% 955 $ 307.472K Aug 31, 2026
QMOM 1.52% 20,100 $ 5.78M Nov 18, 2026
CNEQ 1.48% 39,998 $ 10.857M Jun 30, 2026
FFOG 1.40% 16,061 $ 4.36M Jun 30, 2026
TAX 1.31% 1,034 $ 332.907K Aug 31, 2026
ARKK 1.24% 545,443 $ 156.798M Nov 18, 2026
JGRO 1.09% 341,776 $ 98.25M Nov 17, 2026
ALAI 1.07% 17,708 $ 4.807M Jun 30, 2026
LSEQ 1.00% 510 $ 162.736K Nov 13, 2026
MID 0.99% 3,238 $ 1.043M Aug 31, 2026
MCDS 0.94% 256 $ 73.592K Nov 17, 2026
CANC 0.93% 6,084 $ 1.959M Aug 31, 2026
SXQG 0.61% 1,132 $ 365.568K Nov 12, 2026
GQI 0.60% 5,680 $ 1.542M Jun 30, 2026
TMSL 0.58% 58,231 $ 15.807M Jun 30, 2026
TGRT 0.57% 31,600 $ 9.116M Nov 17, 2026
GPT 0.56% 485 $ 131.653K Jun 30, 2026
CGMM 0.54% 68,183 $ 19.669M Nov 16, 2026
FLDZ 0.53% 80 $ 21.716K Jun 30, 2026
AFGR 0.46% 1,321 $ 381.082K Nov 16, 2026
OASC 0.38% 1,101 $ 354.478K Aug 31, 2026
MMSC 0.34% 597 $ 172.223K Nov 16, 2026
FTQI 0.30% 10,105 $ 2.915M Nov 16, 2026
REMC 0.26% 32 $ 8,686.40 Jun 30, 2026
AVIE 0.25% 145 $ 41.83K Nov 16, 2026
FEAC 0.24% 224 $ 60.805K Jun 30, 2026
MODL 0.23% 8,602 $ 2.335M Jun 30, 2026
ENHU 0.21% 68 $ 19.617K Nov 16, 2026
FMDE 0.16% 43,990 $ 11.941M Jun 30, 2026
AFLG 0.16% 5,153 $ 1.487M Nov 16, 2026
PEPS 0.15% 164 $ 44.518K Jun 30, 2026
LCTU 0.14% 5,341 $ 1.541M Nov 16, 2026
HEQQ 0.13% 132 $ 37.946K Nov 17, 2026
VFMO 0.11% 6,573 $ 2.116M Aug 31, 2026
BALQ 0.10% 146 $ 42.118K Nov 16, 2026
BALI 0.09% 4,854 $ 1.4M Nov 16, 2026
XMAG 0.08% 542 $ 175.033K Nov 13, 2026
PHEQ 0.07% 354 $ 96.093K Jun 30, 2026
DFUS 0.07% 43,551 $ 14.064M Nov 12, 2026
DFSU 0.06% 4,311 $ 1.392M Nov 12, 2026
TACU 0.05% 31 $ 8,942.88 Nov 17, 2026
DFAU 0.05% 18,709 $ 6.042M Nov 12, 2026
IALT 0.04% 9,752 $ 2.813M Nov 16, 2026
MSLC 0.04% 4,974 $ 1.601M Aug 31, 2026
DCOR 0.04% 50,888 $ 16.434M Nov 12, 2026
AVLC 0.03% 1,546 $ 445.99K Nov 16, 2026
DYNF 0.03% 37,754 $ 10.891M Nov 16, 2026
DFAC 0.03% 77,763 $ 25.113M Nov 12, 2026
NTSD 0.02% 31 $ 8,414.95 Jun 30, 2026
GDE 0.02% 252 $ 81.134K Aug 31, 2026
NTSX 0.02% 818 $ 222.046K Jun 30, 2026
NPFE 0.00% 112 $ 29.989K Jul 31, 2026
AVUS 0.00% 531 $ 153.183K Nov 16, 2026
AVSU 0.00% 32 $ 9,231.36 Nov 16, 2026